According to several experts, none of the individuals who received a cancer diagnosis after using Zantac had a family history of the condition or a genetic predisposition to it. Instead, health care providers told the patients that illness was caused by their environment, which might have included NDMA exposure.
Zantac, also known as ranitidine, is a medication that belongs to the H2RA subclass. These medications reduce the amount of acid that is produced by the stomach. Before this point, medical personnel treated patients suffering from the following conditions using Zantac:
The version of Zantac that contained ranitidine is no longer sold in the United States. This page only contains information about the side effects of Zantac that was manufactured using ranitidine. The information does not apply to Sanofi’s new Zantac 360, which was manufactured with famotidine and is not impacted by the market removal.
In clinical trials, the researchers from France showed that the rate of side effects linked with Zantac was extremely comparable to that of patients who took a placebo, also known as an inactive drug. Their findings were published in a publication from the United States.
Concerns over Zantac’s possible connection to cancer stem from ranitidine’s ability to produce NDMA, which raises the possibility of a relationship between the two. Research conducted in the 1980s raised the possibility of a link between the substance in question and the manufacture of NDMA.
In 1983, two Italian medical researchers made the discovery that there may be a link between ranitidine, the chemical name for Zantac, and the carcinogenic toxin NDMA. Zantac has an ingredient called “DMA” (dimethylamine), which, when combined with the “N” found in foods that are typically eaten, can cause the formation of nitrosamines, nitrites, and nitrates. Zantac is always used with food, despite the fact that early researchers were genuinely of the opinion that this shouldn’t be done.
Because there is now only limited evidence that the NDMA found in ranitidine leads to cancer, researchers have not been able to calculate a precise risk level for it.
According to reports, researchers at the Memorial Sloan Kettering Cancer Center have discovered a correlation between a higher risk of acquiring specific tumours and the chances of having certain tumours.
People who took ranitidine-containing Zantac and later developed cancer have begun filing ranitidine lawsuits in response to the recalls of both ranitidine and Zantac by their respective manufacturers owing to the possibility of cancer. The FDA found that ranitidine, the primary component of Zantac, contains a substance known as N-nitrosodimethylamine (NDMA), which has the potential to cause cancer in humans.
Because of the possibility of NDMA contamination, the FDA has advised all relevant manufacturers that ranitidine-based Zantac sales in the United States will be discontinued as of April 2020. However, the FDA is unable to determine how long NDMA has been present in Zantac since they do not know how long the drug has been on the market. The amount of NDMA found in a drug rises the longer it is available for purchase. The new pharmaceutical from Sanofi called Zantac 360, which contains famotidine, is exempt from the recalls and legal measures being taken against the company.
If you have been diagnosed with cancer after taking Zantac, it is important that you discuss your medical history with ranitidine with your primary care physician. It is possible that they will use it to determine a diagnosis and potential courses of treatment for you.
Always make sure to keep all of your medical records and the notes your doctor gives you. If the prerequisites are met, there is a possibility that you could be entitled to launch a case against Zantac.
An individual must have a history of using Zantac, have been diagnosed with cancer, and establish a link between their cancer diagnosis and Zantac use in order to be eligible for legal action, according to the attorneys representing Zantac. Users of the Zantac brand name are the only ones who are eligible to file claims, as ranitidine in its generic form is no longer protected by this policy.
A claim can only be evaluated effectively by a lawyer, who can also provide assistance in gathering supporting documentation and medical records to bolster a client’s case.
Concerns Regarding Your Health in the Event That You Have Been Diagnosed with Zantac Cancer